Evidence map›Paper›PMID 36937210›Full record

ArticleIranian journal of pharmaceutical research : IJPR2022

Oxilipin, a New Anti-cancer Phospholipase A2-like Protein from Iranian Caspian Cobra,

Seyed Mahdi Shekarabi, Hadi Parsian, Kamran Pooshang Bagheri, Delavar Shahbazzadeh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Seyed Mahdi ShekarabiBiotechnology Research Center, Medical Biotechnology Department, Venom and Biotherapeutics Molecules Lab., Pasteur Institute of Iran, Tehran, Iran.
Hadi ParsianDepartment of Clinical Biochemistry, Babol University of Medical Sciences, Babol, Iran.ORCID https://orcid.org/0000-0002-3965-7566
Kamran Pooshang BagheriBiotechnology Research Center, Medical Biotechnology Department, Venom and Biotherapeutics Molecules Lab., Pasteur Institute of Iran, Tehran, Iran.
Delavar ShahbazzadehBiotechnology Research Center, Medical Biotechnology Department, Venom and Biotherapeutics Molecules Lab., Pasteur Institute of Iran, Tehran, Iran.ORCID https://orcid.org/0000-0002-9066-8666

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The discovery of novel anti-cancer agents from natural resources is highly necessary. Concerning the above problem, the purpose of this study was to discover an anti-cancer compound from Caspian cobra venom. Fractionation of Caspian cobra venom was performed by gel filtration and IEX chromatography. The results showed an anti-cancer protein nominated as Oxilipin. Activity and toxicity of Oxilipin were studied on the colon SW480 cancer cell line using MTT, LDH release, PI staining, morphological cell analysis, hemolysis, and anti-proliferation assays. Oxilipin, an 11kDa protein purified from the venom of the Caspian cobra. LC/MS/MS analysis of obtained protein showed homology with Phospholipase A2 from ‎

Indexed as

Anti-cancerCaspian CobraColorectal Cancer Cell LinePLA2SW480

Identifiers

PMID36937210
PMCPMC10016118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.